Fractures are associated with considerable socioeconomic burden1 and may be associated with delayed union and nonunion.2 Delayed union and nonunion can result in loss of function and significant pain and are associated with increased treatment costs and reduced quality of life.2 Factors contributing to delayed union and nonunion include fracture characteristics (e.g., fracture displacement, severity of injury to the soft tissue envelope, infection at the fracture site), iatrogenic factors (e.g., medications, such as anticoagulants, steroids, anti-inflammatory drugs, radiotherapy) and patient characteristics (e.g., vitamin deficiencies, smoking habits).3 The standard care for delayed union and nonunion include nonsurgical (e.g., cast immobilization) and surgical treatment (e.g., external fixation, plating, internal intramedullary nail fixation). Adjunct interventions, such as bone stimulators, are commonly used to facilitate fracture healing. A 2008 survey of 450 Canadian trauma surgeons (79% response rate) showed that 45% of surgeons used bone growth stimulators as part of their treatment strategies for managing fractures.4 Of these, an equal number used low-intensity pulsed ultrasonography (LIPUS) and electrical stimulators (ESTIM). The US Food and Drug Administration approved LIPUS in 1994 for accelerating fresh fracture healing and in 2000 for the treatment of existing nonunions.5 The technique is non-invasive, and its waves induce micromechanical stress in the fracture site, stimulating molecular and cellular responses involved in fracture healing.6,7 Previous systematic reviews evaluating the effectiveness of LIPUS have suggested a moderate effect on surrogate end points (e.g., reducing time to radiographic union), but inconsistent effects on measures of direct importance to patients, such as return to function.8–11 The use of ESTIM is another noninvasive technique marketed for improving fracture healing. It is believed to affect many cellular pathways, including growth factor synthesis, cytokine production, proteoglycan and collagen, which ultimately stimulate pathways that enhance fracture healing.12–14 Previous systematic reviews evaluating ESTIM for healing existing nonunions concluded that the current evidence is inconsistent — neither showing a significant impact nor confidently rejecting the therapeutic effect of ESTIM.3,15 There have been no comparative studies evaluating LIPUS versus ESTIM for fracture healing. Although the clinical effectiveness for both LIPUS and ESTIM is inconsistent, use of these modalities remains high. In 2012, sales of bone stimulators in the United States were approximately $700 million annually, with a projected growth of 6% per year.16 To best inform evidence-based patient care, it is often desirable to compare competing therapies. Network meta-analysis techniques are powerful approaches that allow for indirect comparison of interventions that have not been directly compared.17,18 The main purpose of this study was to systematically review the LIPUS and ESTIM literature and perform a network meta-analysis of these 2 treatments for accelerating fracture healing in both fresh fracture and nonunion populations.